Diabetic macular edema

This study tests an experimental drug called THN391, given as an injection into the eye, for people with diabetic macular edema (DME) — a condition where fluid builds up in the retina due to diabetes, causing vision loss. The trial involves 21 adults aged 18 to 80 with DME and vi…

This phase 3 trial tests whether an experimental drug called MK-8748 can treat diabetic macular edema (DME), a condition where fluid builds up in the retina and blurs vision. About 960 adults with DME will receive either MK-8748 or the standard treatment aflibercept via eye injec…

This early-stage trial tests an experimental drug called RO7823653, given as an eye injection alone or with an approved drug (faricimab), for people with diabetic macular edema—a condition where diabetes causes fluid buildup and vision loss in the center of the eye. The study wil…

This study tests a new eye injection called KIO-104 for people with macular edema, a condition where fluid builds up in the eye and blurs vision. About 28 adults will receive multiple doses to see if the drug is safe and helps reduce swelling. The goal is to find a steroid-free o…

This study tests an oral medication called BI 1815368 in 300 adults with center-involved diabetic macular edema, a common cause of vision loss in diabetes. Participants take tablets twice daily for about 11 months, and doctors compare vision changes between those on the drug and …

This study tests a new medicine called BI 3812465 for people with diabetic macular edema, a condition that causes swelling in the center of the eye and can lead to vision loss. The trial has two parts: first, a small group gets low to high doses to check safety, then a larger gro…

This phase 3 trial compares an experimental drug, tabirafusp tedromer, against the standard treatment aflibercept for people with diabetic macular edema (DME), a leading cause of vision loss in diabetes. About 910 adults with DME will receive injections into the eye and be follow…

This early-stage trial tests a new drug called OCU200, given as an injection into the eye, for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). The study will include 24 participants and will primarily check for safety and side effects…

This trial investigates whether people with diabetic macular edema can safely monitor their vision and eye health at home instead of making frequent hospital visits. Participants use a home vision tester and a portable eye scanner every four weeks, with results sent to their doct…

This study tests a new medicine called AVT29 against an approved drug, Eylea HD, for people with diabetic macular edema (DME), a leading cause of vision loss in diabetes. About 256 adults with DME will receive either AVT29 or Eylea HD to see if AVT29 works just as well at improvi…

This study tests a new eye medication called BAT5906 against an approved drug (Lucentis) for people with diabetic macular edema, a condition that causes vision loss in diabetes. About 406 adults with type 1 or type 2 diabetes will receive injections into the eye and be followed f…

This early-phase study tests a gene therapy called LX111 for diabetic macular edema (DME), a condition that causes vision loss due to swelling in the retina. About 32 adults with DME will receive a single injection into the eye. The main goals are to check safety and see if it he…

This early-phase trial is testing an oral drug called Kamuvudine-9 (K9) in 10 adults with diabetic macular edema, a condition that causes vision loss. The study aims to see if K9 is safe and whether it improves vision compared to a placebo. Participants will take either K9 or pla…

This study tests a micropulse laser for diabetic macular edema, a condition causing vision loss in people with diabetes. Fifty participants with initial or stubborn swelling will receive the laser treatment. Researchers will measure changes in vision and retinal thickness to see …

This study compares having one laser treatment versus several sessions for a serious diabetic eye condition that can cause blindness. Researchers want to see which approach is safer and works better. The study will involve 40 adults with type 1 or type 2 diabetes who have this ey…

This study tests whether levosulpiride, a drug already used for other conditions, can safely improve vision and reduce retinal swelling in people with diabetic retinopathy and diabetic macular edema. About 120 adults aged 40-69 with mild to moderate eye damage will receive either…

This early-stage trial tests an oral drug called MS-553 in 45 people with diabetic macular edema, a condition that causes vision loss in people with diabetes. Participants take the drug daily for 8 weeks. The main goal is to check safety, but researchers will also measure changes…

This study tests whether people with severe diabetic macular oedema (swelling in the center of the retina) can switch from regular eye injections to a gentle laser once the swelling drops below a certain level. 264 adults with type 1 or type 2 diabetes will be randomly assigned t…

This study compares two drugs, aflibercept and bevacizumab, given as eye injections to treat diabetic maculopathy, a complication of diabetes that can blur vision. About 102 Iraqi patients with type 2 diabetes will receive monthly injections for three months. Researchers will mea…

This study compares two ways of screening for diabetic eye disease: using artificial intelligence to read retinal photos versus having eye doctors review them. About 922 adults with diabetes will get their eyes photographed in a primary care clinic. The goal is to see if AI can m…

Researchers are testing an experimental oral drug called BGE-102 in adults with diabetic macular edema, a condition where fluid leaks into the center of the retina and blurs vision. The trial enrolls about 180 people with type 1 or type 2 diabetes and center-involved DME. Partici…

This study follows 100 adults with diabetic eye disease who are already receiving standard anti-VEGF injections for swelling in the center of the retina. Researchers will use advanced vision tests and imaging to track changes over time. The goal is not to test a new drug, but to …

This study tracks eye pressure in 100 people receiving a larger-volume injection of Aflibercept (0.07mL) for macular diseases like age-related macular degeneration. Researchers measure pressure right after the injection and at several time points, then check for any nerve damage …

This study will analyze health records from 2009 to 2024 to find out how many people in Germany have three serious eye conditions: wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Researchers will look at data from two large German health …

This study compares two eye injections—faricimab and a biosimilar version of ranibizumab—in 100 adults with diabetic retinopathy. Researchers will use eye scans (OCT and OCT angiography) to see which drug leads to better early changes in the retina after three monthly doses. The …

This study is for people with diabetic macular edema, a condition that causes vision loss. Researchers want to see if certain substances in the blood and patterns on eye scans can predict how well a patient will respond to two common treatments: anti-VEGF injections or a dexameth…